ArticleChina CDC weekly2024
Risk Assessments for Type 1 Wild Poliovirus and Type 2 Vaccine-Derived Poliovirus Importation and Transmission - China, 2023.
Article in China CDC weekly, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: All countries face the potential threat of imported polioviruses, including both wild type and circulating vaccine-derived polioviruses. In response, we conducted a province-level assessment in China to evaluate the risk of importation and transmission of type 1 wild poliovirus (WPV1) and type 2 vaccine-derived poliovirus (VDPV2). Methods: Distinct risk assessment tools for WPV1 and VDPV2 were employed, incorporating three primary indicators - population immunity, poliovirus surveillance, and importation risk. WPV1 was assessed using 13 secondary indicators, whereas VDPV2 utilized 21 secondary indicators. Assessments used comprehensive provincial data from the preceding five years. Scores (S-values) were derived from the secondary indicators' criteria and ratings, and used to classify the provincial-level administrative divisions (PLADs) into three risk categories: high, medium, and low. The top 10% of PLADs were designated as high-risk, with the remaining provinces equally distributed into medium- and low-risk categories. Results: In 2023, Xizang, Qinghai, and Xinjiang PLADs faced the highest risk of WPV1 importation and transmission; Xizang, Shaanxi, and Hainan PLADs were at the greatest risk for VDPV2 importation and transmission. Conclusions: Risk assessment for VDPV2 importation and transmission has identified a distinct set of high-risk provinces compared to those identified by WPV1 risk assessment. Preventive and proactive response measures tailored to the specific risks should be implemented to maintain China's polio-free status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.